

ABBOTT RAPID DIAGNOSTICS

Solutions for Business Resumption & Expansion

OUR MISSION IS TO HELP YOU Overcome your challenges

- Help you to provide a safer environment for your employees and for your business
- Streamline operations to avoid disruptions
- Consistent supply of tests from a reliable source
- Efficient remote oversight and development of processes

Abbott is offering solutions that address your key needs


ABBOTT SOLUTIONS



*High production capacity, suitable both for centralized and decentralized settings;

ABBOTT SOLUTIONS Overview of product applications


The timing of each test is important and can determine a positive or negative result



Sources: Sethuraman, N., Jeremiah, SS., Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. (6 de maio de 2020). doi: 10.1001/jama.2020.8259

ABBOTT SOLUTIONS How the tests work


Alpha, Beta, Delta, Gamma SARS-CoV-2 variants show no impact on the results of these tests



^Products availability may vary by country1. Internal clinical data held on file.

ABBOTT SOLUTIONS Testing applications

Preferred diagnosis solution by test frequency and population size



Abbott solutions can be applied to various testing needs, from one-off to mass testing of small to large populations

Product Details

PRODUCT DETAILS Panbio [™] COVID 19 Ag Rapid Test Device (Nasal)

PERFORMANCE

- Sensitivity: 98.1%
- Specificity: 99.8%

SPECIFICATIONS

- Test time: 15 minutes
- Storage: 2°C 30°C
- Sample Type: Nasal swab
- CE Mark, WHO EUL

*Performance determined from 104 positive samples confirmed with nasal PCR using FDA EUA RT PCR method

*The clinical performance data was also calculated vs nasopharyngeal swab specimens using an FDA EUA RT PCR reference and has a sensitivity of 91.1% (95% CI: 84.2 95.6%) and specificity of 99.7% (95% CI: 98.6 100.0%).



PRODUCT DETAILS Panbio[™] COVID-19 Ag Rapid Test Device (Nasopharyngeal)

PERFORMANCE

- Sensitivity: 91.4% (94.1% for samples with Ct values ≤33)
- Specificity: 99.8%

SPECIFICATIONS

- Test time: 15 minutes
- Storage: 2°C–30°C
- CE MARK, WHO EUL
- Sample Type: Nasopharyngeal swab



PRODUCT DETAILS Panbio TM COVID 19 Antigen Self-Test

PERFORMANCE

- Sensitivity: 98.1%
- Specificity: 99.8%

SPECIFICATIONS

- Test time: 15 minutes
- Storage: 2°C 30°C
- Sample Type: Nasal swab
- CE Mark





*Performance determined from 104 positive samples confirmed with nasal PCR using FDA EUA RT PCR method

*The clinical performance data was also calculated vs nasopharyngeal swab specimens using an FDA EUA RT PCR reference and has a sensitivity of 91.1% (95% CI: 84.2 95.6%) and specificity of 99.7% (95% CI: 98.6 100.0%).

PRODUCT DETAILS ID NOW[™] COVID-19 Assay (Molecular)

SAMPLE TYPE

- Nasal Swab
- Nasopharyngeal (NP) Swab
- Throat Swab

DIRECT SWABS

- 2 Hours at Room Temperature
- Up to 24 hours at 2-8°C

TECHNOLOGY

Utilizes proven isothermal molecular technology in an intuitive platform, providing the fastest molecular results in the market.





The ID NOW COVID-19 assay shows results in 13 minutes or less

PRODUCT DETAILS Panbio[™] COVID-19 IgG/IgM Rapid Test Device (ICO-T402)

PERFORMANCE

FINGERSTICK WHOLE BLOOD

- Sensitivity: 96.2%
- Specificity: 100.0%

VENOUS WHOLE BLOOD¹

- Sensitivity: 96.0%
- Specificity: 95.8%

PLASMA¹ / SERUM²

- Sensitivity: 97.8%
- Specificity: 92.8%



1. EDTA, heparin or sodium citrate can be used as anticoagulants

2. Based on matrix equivalency studies

PRODUCT DETAILS Panbio[™] COVID-19 IgG/IgM Rapid Test Device (ICO-T40203)

PERFORMANCE

FINGERSTICK WHOLE BLOOD

- Sensitivity: 96.2%
- Specificity: 100.0%

VENOUS WHOLE BLOOD¹

- Sensitivity: 96.0%
- Specificity: 95.8%

PLASMA¹ / SERUM²

- Sensitivity: 97.8%
- Specificity: 92.8%



EDTA, heparin or sodium citrate can be used as anticoagulants
Based on matrix equivalency studies

Abbott at a glance

Improving health around the world through life-changing technology



15 Proprietary and confidential — do not distribute

100

WHY ABBOTT? Abbott has been at the forefront in fighting the COVID 19 pandemic



COVID-19 testing has become a part of our daily conversation and we at Abbott are well positioned to help you establish a safer way to return to work.

Abbott Pandemic Defense Coalition

- The molecular point of care ID NOW[™] COVID-19 test targets the RNA dependent RNA polymerase (RdRp) gene.
- The Panbio[™] COVID-19 Ag Rapid Test Device is a rapid antigen detection test (RADT) which targets the protein encoded by the Nucleoprotein (N) gene.
- Panbio[™] COVID-19 IgG/IgM Rapid Test Device is a rapid antibody detection test (RADT) which detects IgG and IgM antibodies against the protein encoded by the Nucleoprotein (N) gene.
- Abbott is closely monitoring the global situation on COVID-19 mutations and provide relevant updates regarding our COVID-19 tests. Additionally, the Abbott Global Viral Surveillance Program has formed a collaborative scientific network known as the "Abbott Pandemic Defense Coalition".
- The Coalition seeks to harness decades of experience from global collaborators to address the evolving COVID-19 pandemic in addition to preparing for a rapid response to future viral threats.

WHY ABBOTT? Leading companies across industries have chosen to work with Abbott

- Airports in emerging Asian markets
- Asian airline
- Global logistics provider
- Global soft drink provider
- Luxury hospitality chain
- Global automotive provider
- Global retailer
- And many more.



WHY ABBOTT? In summary, Abbott is well positioned to support your needs...



Global leader in rapid point of care diagnostics



Reliable, accurate and quality tests



End to end diagnostic products, physical testing* & Digital Solutions



Products designed to optimize your testing

*Some services provided in collaboration with qualified third-party healthcare providers



© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. COL-03033-3.0 07/21